ライフサイエンスコーパス: hypertension

1 n (compared with coronary artery disease and hypertension).

2 refractory to available therapeutics (e.g., hypertension).

3 trol of inflammation plays a central role in hypertension.

4 of unknown cause or familial nephropathy or hypertension.

5 iated with an increased prevalence of masked hypertension.

6 ated prognostic scores in pulmonary arterial hypertension.

7 hydropyridine scaffold and are indicated for hypertension.

8 utonomic neuropathy, arterial stiffness, and hypertension.

9 ng issue with these drugs is that most cause hypertension.

10 as further divided into masked and sustained hypertension.

11 dling and the pathogenesis of salt-sensitive hypertension.

12 o very high rates of subsequent diabetes and hypertension.

13 s in compensatory activity during neurogenic hypertension.

14 ery dissection, fibromuscular dysplasia, and hypertension.

15 nd potentially treat fibrosis in addition to hypertension.

16 flammation, fibrosis, congestion, and portal hypertension.

17 children were 3-6 times more likely to have hypertension.

18 o school age were positively associated with hypertension.

19 ntigen+, and less likely to have diabetes or hypertension.

20 US adults may be misclassified as not having hypertension.

21 f BP self-monitoring to lower BP and control hypertension.

22 gammadelta T cells are associated with human hypertension.

23 tch National Network for Pediatric Pulmonary Hypertension.

24 n functional Budd-Chiari syndrome and portal hypertension.

25 dge on the use of beta-blockers in pulmonary hypertension.

26 ing to neurohumoral activation in neurogenic hypertension.

27 ncreased vascular contractility in pulmonary hypertension.

28 clampsia, term preeclampsia, and gestational hypertension.

29 in heightened sympathetic vasomotor tone in hypertension.

30 tial therapeutic target for the treatment of hypertension.

31 re control, than for patients with essential hypertension.

32 ese mice is a promising therapy for reducing hypertension.

33 ctor FRA2 was restricted to pulmonary artery hypertension.

34 -PH bears similarities to pulmonary arterial hypertension.

35 sure in follow-up of patients with pulmonary hypertension.

36 rotease 17 (ADAM17) activity in experimental hypertension.

37 CI: 2.27-5.23) were strongly associated with hypertension.

38 people with asthma have an increased risk of hypertension.

39 eyes of 100 patients with glaucoma or ocular hypertension.

40 educed cBRS in RA that can be independent of hypertension.

41 ed as a novel treatment option for pulmonary hypertension.

42 e vasoconstrictor response to cold stress in hypertension.

43 or AFL among older adults with a history of hypertension.

44 d identify potential therapeutic targets for hypertension.

45 standing the changes that occur in pulmonary hypertension.

46 patients with open-angle glaucoma and ocular hypertension.

47 take can decrease blood pressure and prevent hypertension.

48 is, and inflammation and plays a key role in hypertension.

49 of patients with heart failure and pulmonary hypertension.

50 7 (TH17) cells, which can also contribute to hypertension.

51 ch BSJYD provides myocardial protection from hypertension.

52 such as chronic nausea, vomiting, pain, and hypertension.

53 In the absence of smoking or hypertension, 0.09% (95% CI, 0.02% to 0.35%) of adult me

54 [2.0-2.6]), prehypertension (1.4 [1.0-1.9]), hypertension (1.9 [1.3-2.9]), overweight (2.0 [1.4-2.9])

55 esity, 3.9 years for diabetes, 1.6 years for hypertension, 2.4 years for physical inactivity, and 4.8

56 ce of type 2 diabetes mellitus (15.5%-5.9%), hypertension (29.7%-19.5%), dyslipidemia (14.0%-6.8%), a

57 Essential hypertension (31.4%, 39.3%, and 76.2%, respectively), hy

58 nts with bevacizumab and octreotide included hypertension (32%), proteinuria (9%), and fatigue (7%);

59 One third of the patients had masked hypertension, 32% had LVH, and 38% had estimated glomeru

60 (subjects with hypertension vs those without hypertension, 32.5 mm(3); 95% CI: 7.7, 57.2; P = .010) w

61 ADS-VASc score was 3.0 (heart failure, 1.4%; hypertension, 54%; diabetes mellitus, 30%; prior stroke/

62 ates of diabetes (398 [37.4%]; P < .001) and hypertension (735 [69.1%]; P < .001), higher body mass i

63 Comorbidities included hypertension (77%), diabetes mellitus (31%), and coronar

64 xceptions of hyperlipidemia (6.1% vs 11.2%), hypertension (9.8% vs 18.4%), osteopenia (41.5% vs 43.1%

65 Chronic hypertension, a driving factor of disease progression in

66 African American Study of Kidney Disease and Hypertension (AASK) and 761 Modification of Diet in Rena

67 African American Study of Kidney Disease and Hypertension (AASK) Cohort Study who exhibited overt pro

68 including anaemia, fever during labour, and hypertension accounted for most of the complications.

69 emerging clinical perspectives on pulmonary hypertension across the broad spectrum of heart failure

70 Hypertension affects nearly 1 of 3 women and contributes

71 It is defined by hypertension after 20 weeks' gestation and proteinuria o

72 Childhood cancer survivors with hypertension after anthracycline exposure are at increas

73 nce of general obesity, central obesity, and hypertension among the children was 11.1%, 19.7%, and 9.

74 and JNC7 guidelines, the crude prevalence of hypertension among US adults was 45.6% (95% confidence i

75 mproved over time in the Enhanced Control of Hypertension and Acute Stroke Study (ENCHANTED) and the

76 on Trial showed that among participants with hypertension and an increased cardiovascular risk, but w

77 ous pathologies including pulmonary arterial hypertension and cardiomyopathy.

78 at a significantly higher risk of developing hypertension and cardiovascular disease.

79 style with high salt consumption can lead to hypertension and cardiovascular disease.

80 ysiological functions mediated by 20-HETE in hypertension and cardiovascular diseases.

81 ions examined, only the relationship between hypertension and diabetes in the adult-parent dyads was

82 lower waist circumference, and lower odds of hypertension and diabetes) and an unfavorable profile (h

83 ance in the control of risk factors (such as hypertension and diabetes).

84 ing and treating medical conditions, such as hypertension and diabetes, that increase stroke risk.

85 remission rates and lower incidence rates of hypertension and dyslipidemia than did nonsurgery group

86 been implicated in resultant obesity-related hypertension and impaired glucose intolerance.

87 RDN caused a complete reversal of hypertension and improved renal function in CKD-RDN shee

88 Overall, subjects with hypertension and increasing age were more likely to have

89 ring exercise occurs in HFpEF independent of hypertension and is correlated with classical hemodynami

90 Her past medical history was notable for hypertension and moderately overweight status (body mass

91 onemia has been associated with intracranial hypertension and mortality in patients with acute liver

92 h the risk of incident respiratory diseases, hypertension and myocardial infarction from the life-cou

93 e impact of smoking on respiratory diseases, hypertension and myocardial infarction, with a particula

94 ed for the treatment of patients with ocular hypertension and open-angle glaucoma.

95 contrast, chronic hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling were not

96 ng or both - are a common cause of childhood hypertension and renal failure.

97 associated with several sequelae, including hypertension and stroke.

98 h features of tubulo-interstitial nephritis, hypertension and tendency for hyperkalemia, though none

99 abetes and hypertension lead to diabetes and hypertension and that the combination of both during pre

100 Other etiologies such as hypertension and trauma were less frequent, and in no ca

101 ctor machine are compared and evaluated with hypertension and two cancer data sets in our study.

102 For example, some hypertension and type 2 diabetes alleles will be associa

103 A 64-year-old woman with a history of hypertension and type 2 diabetes had been in her usual s

104 In contrast, chronic hypertension and type 2 diabetes showed no significant a

105 Venous valves (VVs) prevent venous hypertension and ulceration.

106 tion of participants who were aware of their hypertension and were receiving treatment varied signifi

107 ntricular hypertrophy (LVH) in patients with hypertension and whether reducing the risk of LVH explai

108 n), control (hyperglycemia, dyslipidemia and hypertension) and chronic microvascular and macrovascula

109 was 63+/-13 years, 70% were female, 78% had hypertension, and 22% had PH.

110 ed the heightened CB chemosensory reflex and hypertension, and also stabilized breathing.

111 us vessel anatomy, progressive valvulopathy, hypertension, and atrial scars from previous heart surge

112 ciations of general and central obesity with hypertension, and between body mass index (BMI), waist c

113 lyses between genetic variants and age, sex, hypertension, and body mass index in the AFGen Consortiu

114 Obesity, smoking, diabetes, hypertension, and cardiac and metabolic conditions, but

115 ablished risk factors (hypercholesterolemia, hypertension, and diabetes mellitus).

116 e correlated with cardiac failure, pulmonary hypertension, and encephalomalacia at birth.

117 epatic "recompensation," reduction of portal hypertension, and eventually avoidance of liver transpla

118 otational atherectomy use, number of stents, hypertension, and female sex.

119 ng aorta, typically due to poorly controlled hypertension, and heritable genetic variants.

120 obesity, smoking, diabetes, prehypertension, hypertension, and hypercholesterolemia) as well as prese

121 medications for chronic diseases (diabetes, hypertension, and hyperlipidemia) between 2011 and 2013.

122 drug, especially for patients with resistant hypertension, and is considered by the World Health Orga

123 harmacotherapeutic target for heart failure, hypertension, and other cardiovascular diseases.

124 delivery, maternal pregestational diabetes, hypertension, and psychiatric disorders.

125 d podocyte foot effacement in Ang II-induced hypertension; and early mortality in the renal mass redu

126 yocardial infarction, angina, heart failure, hypertension, arrhythmias, arteriosclerosis, stroke, and

127 In this population, we defined hypertension as systolic blood pressure of at least 140

128 ase are driven by diverse risk factors, with hypertension as the leading contributor.

129 tcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk f

130 em plays a causal role in the development of hypertension, atherosclerosis, and associated cardiovasc

131 sk for FSGS, HIV-associated nephropathy, and hypertension-attributed ESRD among people of recent Afri

132 Among individuals without hypertension based on clinic blood pressure (BP), it is

133 d for masked hypertension, defined as having hypertension based on out-of-clinic BP.

134 Age, hypertension, body mass index, and African-American race

135 67.9 years; 35.3% women; 31.2% blacks) with hypertension but no diabetes mellitus from the SPRINT tr

136 escribed mechanisms are relevant not only in hypertension, but also in the case of healed myocardial

137 s are important for successfully controlling hypertension, but little is known about current patterns

138 tables is associated with lower incidence of hypertension, but the mechanisms involved have not been

139 rrelated with age and use of medications for hypertension, cardiac conditions, diabetes, and hyperlip

140 of treatment and monitoring in patients with hypertension, cardiovascular disease events and subseque

141 Given the increasing prevalence of hypertension, clarifying the mechanistic underpinnings o

142 the hydrocephalus and suspected intracranial hypertension cohort (60% female), and 59.7 (64.4) months

143 AAAD+ patients and 86.67% controls from the hypertension cohort.

144 agen and hyaluronan, leading to interstitial hypertension collapsing blood and lymphatic vessels, lim

145 n a large cohort of unselected patients with hypertension, consecutively referred to our hypertension

146 r uninsured) persistently had lower rates of hypertension control compared with whites.

147 he past several decades, BP has declined and hypertension control has improved.

148 ep apnea with the incidence and morbidity of hypertension, coronary heart disease, arrhythmia, heart

149 ms of right ventricular failure in pulmonary hypertension could be predicted by using supervised mach

150 Chronic thromboembolic pulmonary hypertension (CTEPH) was confirmed in 4 (2.1%) versus 6

151 al basis of chronic thromboembolic pulmonary hypertension (CTEPH) will be accelerated by an animal mo

152 is unclear who should be screened for masked hypertension, defined as having hypertension based on ou

153 prevalence rates of comorbidities (arterial hypertension, diabetes mellitus, and heart failure), and

154 Geographic disparities in prevalent hypertension, diabetes mellitus, and smoking exist withi

155 of geographic variation in the prevalence of hypertension, diabetes mellitus, and smoking within and

156 ognitive impairment were more likely to have hypertension, diabetes mellitus, hyperlipidaemia, prior

157 een the study and control groups in terms of hypertension, diabetes mellitus, ischaemic heart disease

158 When adjusted to sex, hypertension, diabetes mellitus, target vessel, serial s

159 course of obesity and occur independently of hypertension, diabetes, and dyslipidemia.

160 longitudinal changes in fitness and risk for hypertension, diabetes, and metabolic syndrome over the

161 0% (645/1,611) of all participants developed hypertension, diabetes, and metabolic syndrome, respecti

162 ntake, physical inactivity, current smoking, hypertension, diabetes, and obesity), and mortality, for

163 lyses adjusted for body mass index, smoking, hypertension, diabetes, and systemic steroid use.

164 uded body mass index >/=30, current smoking, hypertension, diabetes, and total cholesterol >/=200 mg/

165 ults, chronic obstructive pulmonary disease, hypertension, diabetes, obesity, percent of population 6

166 e (LC) exerts beneficial effects in arterial hypertension due, in part, to its antioxidant capacity.

167 refer adults without obesity who do not have hypertension, dyslipidemia, abnormal blood glucose level

168 rs only, preexisting cardiovascular factors (hypertension, dyslipidemia, and diabetes) and preexistin

169 on with an additional metabolic risk factor (hypertension, dyslipidemia, or diabetes) (aOR, 6.54 [95%

170 vel genetic loci for blood pressure, lipids, hypertension, etc.

171 ce base for our current approach to treating hypertension, evaluate the effect of measurement techniq

172 reperfusion injury, urinary obstruction, and hypertension exhibited upregulated expression of renal N

173 endent aldosteronism that increases risk for hypertension exists among normotensive persons.

174 se adults aged 35-75 years, nearly half have hypertension, fewer than a third are being treated, and

175 hemic stroke, late menopause and gestational hypertension for hemorrhagic stroke, and oophorectomy, H

176 EVs) or having clinically significant portal hypertension (for presurgical risk stratification).

177 nine aminotransferase increase (four [11%]), hypertension (four [11%]), and vomiting (three [8%]).

178 In familial pulmonary arterial hypertension (FPAH), the autosomal dominant disease-caus

179 h idiopathic or heritable pulmonary arterial hypertension from London (UK; cohorts 1 and 2), Giessen

180 general population, but data on gestational hypertension (GH) are limited.

181 ter the injection was associated with ocular hypertension, hemorrhagic retinopathy, vitreous hemorrha

182 mmol/L (39.5 mg/dL), respectively; obesity, hypertension, high blood sugar, and regular cigarette sm

183 ), chronic kidney disease (CKD), and treated hypertension (HTN) by age, sex, and race within the Nort

184 alcohol use and CVD risk factors (diabetes, hypertension, hyperlipidemia) or subclinical CVD measure

185 The ability to detect intracranial hypertension (ICP >/= 20 mm Hg) was highest for ONSD (ar

186 ncludes the sections: CV Medicine & Society, Hypertension, Imaging, Metabolic & Lipid Disorders, Rhyt

187 study sought to determine the prevalence of hypertension, implications of recommendations for antihy

188 We determined BP thresholds for ambulatory hypertension in a US population-based sample of African

189 43 incident patients with pulmonary arterial hypertension in cohort 3 (p=0.0133).

190 h idiopathic or heritable pulmonary arterial hypertension in cohort 4, with 4.4 years' follow-up and

191 Participants with known hypertension in communities that had all four drug class

192 reported that Efnb3 gene deletion results in hypertension in female but not male mice.

193 cells might contribute to the development of hypertension in humans.

194 Having asthma was inversely associated with hypertension in men (OR: 0.62, 95% CI: 0.41-0.91).

195 reastfeeding may reduce the risk of incident hypertension in middle age.

196 to better control of RA secondary to portal hypertension in patients with cirrhosis, compared with a

197 gy, and management implications of pulmonary hypertension in patients with obstructive hypertrophic c

198 be included in the pharmacologic therapy for hypertension in patients with Type 2 diabetes mellitus.

199 Air pollution has been linked to hypertension in the general population, but data on gest

200 sly we demonstrated massive albuminuria with hypertension in uninephrectomized, aldosterone-infused,

201 having asthma was positively associated with hypertension in women (OR: 2.19, 95% CI: 1.19-4.02).

202 logy might be differentially associated with hypertension in young adults depending on sex.

203 the specific relationship between asthma and hypertension in young adults.

204 es on gait speed in addition to age, sex and hypertension independent from brain atrophy.

205 clarifying the mechanistic underpinnings of hypertension-induced alterations in neurovascular functi

206 In conclusion, BSJYD suppressed hypertension-induced cardiac hypertrophy by inhibiting t

207 Hypertension induces considerable cardiac remodelling, s

208 ats exposed to either ST- or LT-IH exhibited hypertension, irregular breathing with apnoeas, an augme

209 GFR1 in regulating renal processes linked to hypertension is unclear.

210 to renal sodium retention and salt-sensitive hypertension is unknown.

211 ocumented that both gestational diabetes and hypertension lead to diabetes and hypertension and that

212 d systemic vasculopathy, including pulmonary hypertension, leg ulcers, priapism, chronic kidney disea

213 othesis that genetic susceptibility loci for hypertension may serve as predictors for development of

214 Pulmonary hypertension (mean pulmonary artery pressure, >/=25 mm H

215 adverse events were neutropenia (n=2 [5%]), hypertension (n=2 [5%]), insomnia (n=1 [2%]), tinnitus a

216 calculated the performance of HealthLNK for hypertension, obesity, and diabetes mellitus diagnosis b

217 associations between common mental disorder, hypertension, obesity, and high cholesterol in parents a

218 developing obesity, cardiovascular disease, hypertension, obesity-related cancers, and dental caries

219 dies are hyperactive at rest, e.g. essential hypertension, obstructive sleep apnoea and heart failure

220 tion during deoxycorticosterone acetate-salt hypertension occurs selectively on neurons, and neuronal

221 Eligible patients were adults with resistant hypertension (office systolic blood pressure >/=160 mm H

222 development of POAG in patients with ocular hypertension (OHT) and the predictive factors for ODH ar

223 Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolon

224 y protein excretion rate, or the presence of hypertension or hematuria at the time of diagnosis.

225 rgan or limb ischemia, or new uncontrollable hypertension or pain.

226 ignificant differences in residual pulmonary hypertension or RV dysfunction.

227 fidence interval [CI] = 1.3-2.3), history of hypertension (OR = 1.6, 95% CI = 1.2-2.3), increased sys

228 s (OR, 1.07; 95% CI, 0.63-1.84; P = .80) and hypertension (OR, 0.85; 95% CI, 0.50-1.45; P = .55).

229 those without to report chronic conditions (hypertension: OR [odds ratio] 1.43; heart disease: OR 1.

230 erved enhanced gut-neuronal communication in hypertension originating from paraventricular nucleus of

231 ment prevented the development of DN-related hypertension (P < 0.001), the increase of urine albumin

232 ures versus isolated postcapillary pulmonary hypertension (P<0.05).

233 at monocrotaline model of pulmonary arterial hypertension (PAH) are described.

234 sociated with survival in pulmonary arterial hypertension (PAH) at the time of diagnosis.

235 isk, however, its role in pulmonary arterial hypertension (PAH) has not been determined.

236 notype and BPD-associated pulmonary arterial hypertension (PAH) in BPD mouse models, which, conversel

237 vidence for alteration in pulmonary arterial hypertension (PAH) in which apelin signaling is downregu

238 Pulmonary arterial hypertension (PAH) is an obstructive disease of the prec

239 RATIONALE: Pulmonary arterial hypertension (PAH) is an obstructive vasculopathy charac

240 guidelines for pediatric pulmonary arterial hypertension (PAH) is hampered by lack of pediatric clin

241 t would be beneficial for pulmonary arterial hypertension (PAH) remains to be explored.

242 ve vascular remodeling in pulmonary arterial hypertension (PAH) that is hereditary, idiopathic, or as

243 d as a cause of angina in pulmonary arterial hypertension (PAH).

244 In pulmonary hypertension patients, the asymptotic pressure at which

245 RATIONALE: Pediatric pulmonary hypertension (PH) is a heterogeneous condition with vary

246 Portal hypertension (PH) is a major cause of morbidity and mort

247 An emerging metabolic theory of pulmonary hypertension (PH) suggests that cellular and mitochondri

248 isease is the most common cause of pulmonary hypertension (PH).

249 terase inhibition, in experimental pulmonary hypertension (PH).

250 macrophages in the pathogenesis of pulmonary hypertension (PH).

251 pite increases in vascular risk factors (eg, hypertension prevalence increased from 67% to 81% among

252 higher prevalence of unsuccessfully treated hypertension (prevalence ratio = 1.45, 95% confidence in

253 Portal vein hypertension (PVH) in liver cirrhosis complicated with p

254 ns of patients in the LVP+A group had portal hypertension-related bleeding (18% vs 0%; P = .01) or he

255 e subsets involved in the pathophysiology of hypertension remain unclear.

256 riate target for BP in patients with CKD and hypertension remains uncertain.

257 controlled hyperglycemia, hyperlipidemia and hypertension, respectively.

258 verteporfin uptake, suggesting interstitial hypertension results in vascular compression and decreas

259 3 single nucleotide polymorphisms with human hypertension risks, using 3,448 patients with type 2 dia

260 e [aMED], and the Dietary Approaches to Stop Hypertension score) and colorectal cancer risk in the Mu

261 Analysis of human subjects with essential hypertension showed 2.6-fold increase in SOD2 acetylatio

262 of hydrocephalus and idiopathic intracranial hypertension.SIGNIFICANCE STATEMENT Effective disposal o

263 both ischemic and hemorrhagic stroke, while hypertension, smoking, diet, and physical inactivity are

264 ed multiple imputation to impute ABP-defined hypertension status for NHANES participants and estimate

265 al animals and in humans are associated with hypertension, stroke, myocardial infarction, and vascula

266 After pooling data from the Masked Hypertension Study (n = 811), a cross-sectional clinical

267 5.2 mm(3); 95% CI: 7.1, 83.4; P = .020), and hypertension (subjects with hypertension vs those withou

268 using the combination of pulmonary arterial hypertension-targeted therapies and LT in patients who a

269 nts who were treated with pulmonary arterial hypertension-targeted therapies before LT resulted in si

270 y, we identified a population with essential hypertension that was frequency matched by decade of age

271 Compared with essential hypertension, the excess risk for cardiovascular events

272 In pulmonary hypertension, the right ventricle adapts to the increasi

273 therapy can exert off-target effects causing hypertension, thromboembolism, QT prolongation, and atri

274 tients from isolated postcapillary pulmonary hypertension to Cpc-PH, which is characterized by an adv

275 h idiopathic or heritable pulmonary arterial hypertension to improve risk stratification.

276 an analysis of genetic data from the Ocular Hypertension Treatment Study.

277 and annually thereafter (more frequently if hypertension treatment was adjusted on the basis of ambu

278 within the DASH (Dietary Approaches to Stop Hypertension Trial)-Sodium Trial to further our understa

279 den in the United States, including obesity, hypertension, type 2 diabetes mellitus, and cardiovascul

280 After matching for age, sex, hypertension, type 2 diabetes, previous stroke, and anti

281 years +/- 17) with newly diagnosed pulmonary hypertension underwent cardiac magnetic resonance (MR) i

282 hypertension, consecutively referred to our hypertension unit, by 19 general practitioners from Tori

283 in gammadelta T cells blunted Ang II-induced hypertension, vascular injury, and T-cell activation; an

284 ; P = .020), and hypertension (subjects with hypertension vs those without hypertension, 32.5 mm(3);

285 participants with versus without any masked hypertension was 0.681 (95% confidence interval, 0.640-0

286 The angiotensin II-induced hypertension was attenuated by cotreatment with the alph

287 Hypertension was defined according to the Fourth Report

288 Unsuccessfully treated hypertension was defined as daytime ambulatory BP of at

289 the alphaAnalogue on angiotensin II-induced hypertension was investigated over 14 days.

290 The incidence of hypertension was positively related to (calibrated) sodi

291 Interestingly, pulmonary hypertension was present in 13 patients at baseline and

292 Hypertension was set as the mediator.

293 Among individuals whose hypertension was treated but not controlled, 81.5% (81.3

294 I)-aldosterone (Ald) infusion mouse model of hypertension was utilised in this study.

295 These changes in gut pathology in hypertension were associated with alterations in microbi

296 intact older adults receiving treatment for hypertension were studied from 1997 to 2007 in the Healt

297 ported for human' diet since weaning lead to hypertension, which appears to rely on sodium-driven neu

298 identifies patients with pulmonary arterial hypertension with a high risk of mortality, independent

299 tment of hyperglycemia with rosiglitazone or hypertension with lisinopril partially reduced ACR, cons

300 SBP throughout the range of pre- and stage 1 hypertension, with progressively greater reductions at h